Novo Nordisk said Monday that its sickle cell disease pill succeeded in a late-stage study. However, the data came in behind expectations the company set last year. Etavopivat cut the occurrence of the painful sickle cell complications known as vaso-occlusive crises (VOCs) by 27% compared with placebo, hitting one of the trial’s co-primary endpoints. However, the company’s then-head of rare disease Ludovic Helfgott told Endpoints News last year that Novo was hoping to see a 50% cut. Nonetheles

New data demonstrate the IL-22 AND-Body™ therapeutic, AMP-220, selectively targets gut tissue, conferring improved therapeutic efficacy and tolerability in vivo IND-enabling studies for AMP-220 are ongoing April 20, 2026 -- Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced new preclinical data for AMP-220, a gut-targeted IL-22 AND-Body™ therapeutic. The data wer

ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) [1],[2] SCLC is an aggressive form of lung cancer, accounting for 10-15% of all lung cancer diagnoses [3]-[6] Lung cancer is the leading cause of cancer death in Australia and among men in Singapore, and the second highest among Singaporean women [7]-[9] April 20, 20

The acquisition of Neurona will put UCB in both the epilepsy and cell therapy space, even as many of its fellow pharmas move away from the latter modality. UCB is fronting $650 million to absorb California-based Neurona Therapeutics to deepen its epilepsy portfolio and expand into regenerative medicine. As part of the acquisition agreement, announced Friday afternoon, UCB will also put up to $500 million on the line in milestone payments. The companies expect to consummate the transaction by t

While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to a new study awaiting peer review. The analysis, shared as a preprint, spotlights the fierce competition between Lilly and Novo in the weight loss drug market. Both companies have been trying to edge the other out by showcasing value-added drug features as well as investing in next-generation approaches and advancing oral formulations.

April 17, 2026 -- The Parker Institute for Cancer Immunotherapy (PICI), today announced that research and expertise from across its network will be showcased at the American Association for Cancer Research Annual Meeting, taking place April 17- 22 in San Diego, California. PICI leaders, investigators, and collaborators are contributing to nearly 100 posters, presentations, and discussions throughout the program - demonstrating the depth and breadth of the network's contributions to the field of

April 17, 2026 -- MastCURe, a high-profile research consortium, has been awarded €1.3M in funding from the Eureka Eurostars program. The collaboration comprising Allegria Therapeutics, Cube Biotech, and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology IA aims to transform the treatment of chronic urticaria, a debilitating mast cell-driven skin disease affecting millions worldwide. MastCURe's innovative approach directly and selectively targets

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-off

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug Administration and to other global regulatory authorities April 13, 2026 -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced positive topline results from its global, randomized, cont

Kailera Therapeutics has pulled off one of the largest biotech IPOs on record, raising $625 million as investor appetite for next-generation obesity drugs shows no signs of abating. The company priced 39.1 million shares at $16 each, which was the top end of its range. Certain existing shareholders had signaled confidence ahead of the debut, indicating plans to purchase about $225 million in the offering, or about 45% of the deal. The offering surpasses Moderna's debut in 2018 when the mRNA va